The boundary between treating disease and engineering enhancement is dissolving. As biotechnology advances from therapeutic intervention to deliberate biological redesign, humanity faces choices it has never had to make before — and governance frameworks that are not prepared to guide them.
In November 2018, a Chinese researcher named He Jiankui announced that he had created the world’s first gene-edited human babies — twin girls, whose embryos had been modified using CRISPR-Cas9 technology to confer resistance to HIV. The scientific community responded with near-universal condemnation. He was subsequently convicted of illegal medical practice and sentenced to three years in prison. The episode was widely described as a cautionary tale about rogue science.
What it also was — though this dimension received less attention — was a preview. The technical capability to make heritable modifications to the human genome exists. It is spreading. The regulatory architecture to govern its use does not exist at the international level, and at the national level varies from prohibition to permissive ambiguity. The question of heritable human genetic modification is not closed. It has been deferred.
Simultaneously, across a broader front, biological technologies are advancing at a pace that is rendering the existing ethics of medicine increasingly inadequate. CRISPR applications for non-heritable somatic cell modification — editing cells in an individual’s body without altering the germline — are already in clinical use for sickle cell disease and certain cancers. Brain-computer interfaces are restoring motor function to paralyzed patients and sensory function to the blind. Synthetic biology is enabling the design of biological systems — organisms, tissues, metabolic pathways — from first principles. Longevity research is producing interventions that appear to extend the healthy lifespan of model organisms, with human trials beginning.
Each of these advances generates its own ethical, social, and governance questions. Together, they constitute a civilizational inflection point: the beginning of an era in which biological humanity is no longer simply given, but partially chosen.
The Therapeutic-Enhancement Boundary
The conventional framework for bioethics distinguishes between therapy — the restoration of normal function impaired by disease or injury — and enhancement — the augmentation of function beyond the normal range. This distinction has done real work in governing medical research and clinical practice. It is increasingly unstable.
Consider vision correction. Glasses and contact lenses are therapeutic: they restore vision to normal range. LASIK surgery is therapeutic with enhancement potential: it can correct vision to better-than-normal acuity. A hypothetical gene therapy that conferred extraordinary visual acuity from birth would be straightforwardly enhancement. Where exactly is the boundary? The honest answer is: there is no principled one. The distinction tracks social convention and the contingent boundary between what medicine currently treats and what it does not, rather than a deep ethical difference.
The same instability appears in cognitive contexts. Methylphenidate (Ritalin) is prescribed therapeutically for ADHD, but is widely used off-label for cognitive enhancement by individuals without the diagnosis. Modafinil is prescribed for narcolepsy and used for wakefulness enhancement by shift workers, students, and military personnel. When drugs developed for one purpose are used for another, the therapeutic-enhancement boundary functions more as a reimbursement framework than as an ethical one.
As gene therapies, brain-computer interfaces, and biological optimization protocols become more capable and more accessible, the pressure on this boundary will intensify. We need more sophisticated ethical frameworks — ones that engage directly with questions of enhancement rather than deflecting them by reference to a therapy-enhancement distinction that the technology is progressively eroding.
Access, Equity, and the Biology of Advantage
The governance question that attracts the most urgent ethical attention is not whether biological enhancement is permissible, but who will have access to it — and what happens to social equality in a world where biological advantage can be purchased.
The concern is not hypothetical. It tracks a well-documented pattern in the history of medical technology. When a new medical intervention is developed, it is typically expensive and accessible only to the wealthy. Over time, if the intervention proves durable, its cost declines and its accessibility broadens. But the gap between early and late adopters is real and consequential: wealthier individuals live longer, healthier lives than poorer ones in every health system in the world, and this advantage is substantially driven by differential access to medical technology.
Biological enhancement at scale would not simply reproduce this pattern. It would potentially amplify it in ways that are qualitatively different from existing health inequality. If cognitive enhancement technologies produce measurable advantages in educational and professional contexts, and if access to those technologies is stratified by wealth, then biological enhancement becomes a mechanism for the intergenerational transmission of advantage — one that operates at the level of the body rather than merely the environment.
This is not a reason to prohibit enhancement research. It is a reason to take the governance of enhancement access with the same seriousness that societies take other questions of distributive justice.
Toward a Governance Framework for Biological Futures
The governance architecture for biotechnology is fragmented, nationally variable, and institutionally slow relative to the pace of technical advance. The International Summit on Human Gene Editing has met three times, producing statements but no binding commitments. The WHO’s Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing has published recommendations that are widely cited and systematically ignored by national governments whose regulatory frameworks diverge from them.
What is needed — and does not yet exist — is an international governance framework for biological research that combines genuine enforceability with the flexibility to accommodate legitimate scientific progress. The model of the International Atomic Energy Agency, with its combination of standard-setting, inspection, and technical assistance functions, offers one template, imperfect but instructive.
Beyond institutional design, the governance of biological futures requires a cultural shift in how technical communities understand their relationship to the societies that give them their mandate and resources. The argument that scientific research is neutral — that its value is inherent and that questions about its social implications are external to the scientific enterprise — is not only philosophically naive. It is socially corrosive. It removes from the scientific community the moral agency that the power of its methods demands.
Biologists designing tools capable of reshaping the human species bear a responsibility that is proportional to that capability. Acknowledging this responsibility — and building it into the culture of biological research — is not a constraint on science. It is a condition of its legitimacy.
The body as system: precisely, rigorously understood, and governed with a sophistication equal to the stakes.